Epidermolysis Bullosa Market Trends, Innovation, and Future Growth Outlook to 2036 - DelveInsight

The Epidermolysis Bullosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermolysis Bullosa pipeline products will significantly revolutionize the Epidermolysis Bullosa market dynamics.

DelveInsight's "Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epidermolysis Bullosa Market Forecast
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Epidermolysis Bullosa Market Report:
• The Epidermolysis Bullosa market size was valued at ~USD 1,700 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2022-2036).
• In June 2026, BioMendics, LLC, a clinical-stage biotechnology company focused on developing innovative therapies for rare genetic skin disorders, has announced that the U.S. FDA has granted Fast Track Designation to BM-3103, formulated as TolaSure® GelTM, for the treatment of Epidermolysis Bullosa Simplex (EBS). The designation marks a significant regulatory milestone for the company as it continues advancing the therapy's clinical development and coincides with its participation in the BIO International Convention 2026, held in San Diego from June 22-25.
• In June 2026, The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BioMendics' BM-3103, developed as TolaSure Gel, for the treatment of Epidermolysis Bullosa Simplex (EBS). The investigational topical therapy leverages the company's liquid-crystal MTORX technology to selectively modulate the mTOR signaling pathway and intermediate filament proteins. By promoting selective autophagy, TolaSure Gel is designed to eliminate mutant keratin aggregates and improve the structural integrity of the epidermis. The Fast Track Designation is intended to accelerate the development and regulatory review of therapies addressing serious diseases with unmet medical needs, offering advantages such as increased FDA engagement, enhanced regulatory guidance, eligibility for Rolling Review, and the potential for Priority Review.
• In June 2026, The U.S. FDA has granted Fast Track designation to BM-3103, an investigational topical therapy formulated as TolaSure Gel, for the treatment of epidermolysis bullosa simplex (EBS), according to a June 23 announcement from BioMendics. This designation complements the therapy's previously awarded Orphan Drug and Rare Pediatric Disease designations, supporting its expedited development as the company continues its Phase II clinical trial in patients with EBS.
• In February 2026, Inmune Bio intends to file regulatory applications this year in the United Kingdom, the United States, and the European Union for approval of CORDStrom, its investigational stem cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has formally submitted a pre-submission package for CORDStrom to the Medicines and Healthcare Products Regulatory Agency (MHRA). This pre-submission serves as a request for regulatory guidance and feedback, aimed at facilitating and streamlining the forthcoming marketing authorization application.
• In September 2025, The FDA has broadened the indication for beremagene geperpavec-svdt (B-VEC; Vyjuvek; Krystal Biotech) to include patients with dystrophic epidermolysis bullosa (DEB) from birth, extending its prior approval for those aged 6 months and older. First approved in May 2023, B-VEC now offers greater flexibility in application and wound care management, as noted by Krystal Biotech.
• In April 2025, Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYNTM (pronounced 'ZEE-vah-skin')-prademagene zamikeracel-as the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe and disabling genetic skin disorder. Currently, there is no cure for RDEB, and ZEVASKYN is the only FDA-approved therapy offering wound treatment through a single application.
• In April 2025, DEBRA Research gGmbH, a German non-profit committed to supporting research and drug development for individuals with Epidermolysis Bullosa (EB), is partnering with Viking Global Investors, CureEB, EBMRF, and Stanford University to invest in Nova Anchora LLC. Nova Anchora is an early-stage, preclinical biotechnology company focused on creating innovative protein therapies for EB. This funding will help advance the company's lead candidate, NvA-011, through preclinical stages and toward IND (Investigational New Drug) readiness.
• In September 2024, In a small real-world study, treatment with Janus kinase (JAK) inhibitors, including upadacitinib and baricitinib, demonstrated greater effectiveness than dupilumab in alleviating itching and skin lesions in individuals with epidermolysis bullosa pruriginosa (EBP). Among five patients on dupilumab, only two achieved a 50% reduction in itching, with none experiencing total relief. In comparison, all five patients treated with JAK inhibitors who had measurable itch scores reported complete relief from itching.
• In 2023, the Epidermolysis Bullosa market size in the US, among the seven major markets (7MM), reached approximately USD 1,300 million, marking the highest figure. It is projected to undergo further growth by 2036.
• In 2023, the United States had the highest prevalence of Epidermolysis Bullosa cases, making up approximately 65% of the total cases among the seven major markets (7MM). Meanwhile, the EU4 countries and the UK comprised around 30%, and Japan accounted for approximately 5% of the total population share in the same year.
• As per DelveInsight's projections, approximately 18,000 cases of Epidermolysis Bullosa simplex, 1,450 cases of junctional Epidermolysis Bullosa, and 8,500 cases of dystrophic Epidermolysis Bullosa were reported in the United States in 2023.
• Key Epidermolysis Bullosa Companies: Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others
• Key Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17,AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others

Epidermolysis Bullosa Overview
Epidermolysis Bullosa (EB) is a group of rare genetic disorders characterized by fragile skin that blisters and forms painful sores in response to minor friction or trauma. This condition is caused by mutations in genes responsible for producing proteins that help anchor the layers of the skin together.

Get a Free sample for the Epidermolysis Bullosa Market Report:
https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Epidermolysis Bullosa Market
The dynamics of the Epidermolysis Bullosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2022-2036.
"In June 2022, the European Commission (EC) approved FILSUVEZ for the treatment of partial-thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older"

Epidermolysis Bullosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidermolysis Bullosa Epidemiology Segmentation:
The Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalence of Epidermolysis Bullosa
• Prevalent Cases of Epidermolysis Bullosa by severity
• Gender-specific Prevalence of Epidermolysis Bullosa
• Diagnosed Cases of Episodic and Chronic Epidermolysis Bullosa

Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ Epidermolysis Bullosa Epidemiological Insights
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epidermolysis Bullosa Therapies and Key Companies
• BPM31510: Berg Pharma
• HOLOGENE-17: Holostem Terapie Avanzate
• AGLE102: Aegle Therapeutics
• RGN-137: RegeneRx Biopharmaceuticals
• PTR-01: BridgeBio Pharma
• INM-755: InMed Pharmaceuticals
• Dabocemagene autoficel: Fibrocell Science
• VYJUVEK: Krystal Biotech

To know more about Epidermolysis Bullosa treatment, visit @ Epidermolysis Bullosa Medications
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Epidermolysis Bullosa Market Drivers
• The rise in the prevalence of epidermolysis bullosa
• Robust clinical pipeline containing emerging drugs with novel RoA and MoA
• Gene and cell therapies are also in the clinical stages of development for the treatment of epidermolysis bullosa
• Increase funding support from organizations such as epidermolysis bullosa Research Partnership

Epidermolysis Bullosa Market Unmet Needs
• Challenges in diagnosis
• Lack of effective treatment
• Challenges in the clinical trial
• Poor disease understanding

Scope of the Epidermolysis Bullosa Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Epidermolysis Bullosa Companies: Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others
• Key Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17,AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others
• Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies
• Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Epidermolysis Bullosa Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.